Extract with effect of relieving acute gouty arthritis and application thereof

Abstract

The invention provides an extract with an acute gouty arthritis relieving effect and application thereof. The medicine is used for treating acute gouty arthritis of mammals. The plantain extract acts on an acute gouty arthritis model rat in a specific intragastric administration mode, the joint swelling degree of the model rat can be remarkably reduced, and inflammatory cell infiltration of synovial tissue is relieved.

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, specifically to extracts that relieve acute gouty arthritis and their applications. Background Technology

[0002] Gout is an acute inflammatory disease caused by elevated blood uric acid levels due to purine metabolism disorders or reduced uric acid excretion, leading to the deposition of urate crystals in the joints and surrounding tissues. Acute gouty arthritis, a common initial symptom of gout, is characterized by the sudden onset of redness, swelling, heat, and pain in the joints, severely impacting patients' quality of life. Currently, clinical treatment for acute gouty arthritis often involves nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine, but these drugs have certain side effects, such as gastrointestinal reactions and liver and kidney damage. Therefore, finding safe and effective natural drugs for the treatment of acute gouty arthritis is of significant practical importance. Summary of the Invention

[0003] In view of this, the present invention aims to provide an extract with the effect of relieving acute gouty arthritis and its application. This addresses the problems of significant side effects and limited efficacy of existing therapeutic drugs, providing a safe and effective treatment option for acute gouty arthritis.

[0004] To achieve the above objectives, the technical solution of the present invention is implemented as follows:

[0005] Application of banana fruit extract in the preparation of drugs for treating acute gouty arthritis.

[0006] In one specific embodiment of the present invention, the drug is a drug for treating acute gouty arthritis in mammals.

[0007] In one specific embodiment of the present invention, the drug is administered orally via gavage for a period of not less than 72 hours.

[0008] In one specific embodiment of the present invention, the volume ratio of banana fruit extract to physiological saline in the drug is 1:10 to 1:100.

[0009] In one specific embodiment of the present invention, the dosage of the drug is 2 mL / time, twice daily.

[0010] In one specific embodiment of the present invention, the drug is a drug for reducing inflammation of synovial tissue.

[0011] In one specific embodiment of the present invention, the drug is a drug that reduces the infiltration of inflammatory cells in synovial tissue.

[0012] In one specific embodiment of the present invention, the banana fruit extract is prepared by the following method: mature banana trees are harvested, and their stems, leaves, and bark are taken, washed, and broken into 2-3 cm fragments as the extractant; the extractant is soaked in a 20%-30% (v / v) NaCl solution and heated with far-infrared light with a wavelength of 7.5-9.5 μm for 8-10 hours; the crude extract is extracted by low-temperature cell disruption at -40℃ to 0℃ for 1-12 hours; the fiber and liquid are separated by centrifugation, and the liquid is filtered and allowed to stand; the supernatant is introduced into a fermentation tank lined with far-infrared light with a wavelength of 7.5-9.5 μm for fermentation to obtain the banana extract.

[0013] Compared with the prior art, the present invention has the following advantages:

[0014] Plantain fruit extract is a food and medicine homology material with a high safety profile. As a common fruit, plantains contain various components including phenolic acids, potassium, phenolic compounds, flavonoids, vitamin C, and dietary fiber. These components may play a positive role in lowering uric acid levels and inhibiting inflammatory responses. The therapeutic effect of plantain extract on a rat model of acute gouty arthritis provides experimental evidence for the development of natural drugs to treat acute gouty arthritis.

[0015] This banana extract, administered via specific gavage to rats with an acute gouty arthritis model, significantly reduced joint swelling and alleviated inflammatory cell infiltration in the synovial tissue. Experimental results showed that, compared to the model group, the banana extract (especially the high-dose group) reduced joint swelling to 0.83±0.05 cm (P<0.001) and the swelling score from 4 to 2 points after 72 hours of administration. This invention provides a novel candidate drug for the clinical treatment of acute gouty arthritis and has promising application prospects. Attached Figure Description

[0016] Figure 1 Results of joint swelling;

[0017] Figure 2 HE staining images of tissue sections from different groups. Detailed Implementation

[0018] Unless otherwise defined, the technical terms used in the following embodiments have the same meanings as commonly understood by those skilled in the art. Unless otherwise specified, the experimental reagents used in the following embodiments are conventional biochemical reagents; and the experimental methods described are conventional methods.

[0019] The present invention will be described in detail below with reference to embodiments.

[0020] The banana fruit extract was prepared by the following method: mature banana trees were harvested, and their stems, leaves, and bark were washed and crushed into 2-3 cm fragments as the extractant; the extractant was soaked in a 25% (v / v) NaCl solution and heated with far-infrared light with a wavelength of 9 μm for 9 hours; the crude extract was extracted by cell wall disruption at -20°C for 10 hours; the fiber and liquid were separated by centrifugation at 3000 rpm for 1 minute, the liquid was filtered through a 100-mesh screen and allowed to stand for 24 hours, and the supernatant was collected; the supernatant was introduced into a fermentation tank lined with far-infrared light with a wavelength of 9 μm and fermented for 90 days to obtain the banana extract.

[0021] 1. Preparation of experimental materials

[0022] Animals: 25 healthy male SPF-grade Wistar rats, 2 months old, weighing 150-180g, were purchased from a regular laboratory animal center;

[0023] Reagents: Sodium urate crystals, Tween 80, physiological saline, colchicine, 4% paraformaldehyde solution, HE staining kit;

[0024] Instruments: electronic balance, vernier caliper, optical microscope, gavage needle.

[0025] 2. Preparation of sodium urate suspension

[0026] Weigh 250 mg of sodium urate crystals and place them in a beaker. Add 9 mL of physiological saline and 1 mL of Tween 80. Heat and stir in a 60°C water bath for 10 min until the solution is well mixed. After cooling to room temperature, a 25 g / L sodium urate suspension is obtained. Prepare and use immediately.

[0027] 3. Animal grouping and treatment

[0028] Grouping: 25 rats were randomly divided into 5 groups of 5 rats each: blank group (normal control), model group, high-dose banana extract group, low-dose banana extract group, and positive control group.

[0029] Modeling: Except for the blank group, the other four groups of rats were modeled according to the method of "Establishment of Acute Gouty Arthritis Model". The blank group was injected with an equal volume of physiological saline into the joint cavity.

[0030] The establishment of an acute gouty arthritis model (to verify the efficacy of banana extract) was carried out as follows:

[0031] Model animals: Healthy male SPF-grade Wistar rats, 2 months old, weighing 150-180g, were selected and acclimatized for 1 week;

[0032] Modeling reagent: 25g / L sodium urate (MSU) suspension (Preparation method: Weigh 250mg sodium urate crystals, add 9mL physiological saline and 1mL Tween 80, heat and stir to mix well);

[0033] Modeling procedure: Under sterile conditions, insert the tibialis tendon at a 45° angle into the dorsal side of the right ankle joint of the rat and inject 0.2 mL of the above MSU suspension; the normal control group was injected with an equal volume of physiological saline.

[0034] Model success criteria: Rats whose joint circumference was measured 6 hours after modeling and whose swelling (difference in circumference before and after modeling) was higher than the upper limit of the normal range (95% confidence level) were considered to have successfully formed a model.

[0035] Administration: Administration began 1 hour after successful model establishment. The blank control group and the model group were given saline by gavage (2 mL / time, twice daily); the high-dose banana extract group was given a 1:10 diluted banana extract solution by gavage (2 mL / time, twice daily); the low-dose banana extract group was given a 1:100 diluted banana extract solution by gavage (2 mL / time, twice daily); the positive control group was given colchicine suspension (0.3 mg / kg / d) by gavage (2 mL / time, twice daily); administration continued for 72 hours.

[0036] The dosing regimen for the banana extract is as follows:

[0037] Dilution ratio: The banana extract was diluted with physiological saline at volume ratios of 1:10 (high dose) and 1:100 (low dose) to obtain banana extract dilutions;

[0038] Administration method: Oral gavage;

[0039] Dosage: 2 mL each time, twice daily;

[0040] Dosage cycle: Continuous administration for 72 hours.

[0041] 4. Indicator Testing

[0042] Following the "efficacy evaluation index" method, the joint circumference and joint swelling of rats were measured at 6h, 12h, 24h, 48h, and 72h after drug administration, and the joint swelling of rats was scored. Rats were sacrificed 72h after drug administration, and synovial tissue was taken for HE staining and pathological observation.

[0043] The efficacy evaluation indicators are:

[0044] Joint swelling index: The circumference of the same marked site on the right ankle joint of rats was measured by the suture method, the swelling degree (difference in circumference before and after modeling) was calculated, and the joint swelling degree was scored.

[0045] Pathological indicators: Synovial tissue from the right ankle joint was taken, fixed in 4% paraformaldehyde for 24 hours, embedded in paraffin, sectioned, stained with hematoxylin and eosin (HE), and the infiltration of inflammatory cells was observed under a light microscope.

[0046] Experimental results

[0047] Joint swelling index

[0048] The control group (normal control) rats had a joint swelling score of 0 throughout the entire experimental period, with no signs of redness or swelling, and the joint appearance and function were completely normal.

[0049] Six hours after modeling, the joint swelling score of rats in the model group reached 2 points, and it rose to 4 points after 24 hours, with mild redness and swelling of the joints.

[0050] After 72 hours of administration of high-dose banana extract (1:10 dilution), the joint swelling score of rats decreased to 2 points, and the degree of joint swelling was significantly improved.

[0051] After 72 hours of administration, the joint swelling score in the low-dose group (1:100 dilution) of banana extract decreased to 3 points, and the degree of symptom improvement was lower than that in the high-dose group.

[0052] The positive control group (colchicine, 0.3 mg / kg / d) maintained a joint swelling score of 2 points 72 hours after administration, which was comparable to the high-dose banana extract group.

[0053]

[0054] The results are as follows Figure 1 As shown, the joint circumference of each dose group of banana extract and the colchicine group (positive control group) was lower than that of the model group, and the circumference decreased over time. Among them, the colchicine group showed the most significant swelling relief effect, and the high dose group of banana extract was better than the low dose group, which showed a certain dose dependence.

[0055] Pathological indicators

[0056] The results are as follows Figure 2 As shown, the synovial tissue in the blank group showed no inflammatory cell infiltration and its structure remained intact;

[0057] The synovial tissue of the model group showed infiltration of a large number of inflammatory cells (such as neutrophils and macrophages) and significant tissue edema;

[0058] The high-dose group of banana extract showed a significant reduction in the number of inflammatory cells infiltrating the synovial tissue and a reduction in tissue edema;

[0059] The low-dose banana extract group showed less inflammatory cell infiltration than the model group, but more than the high-dose group.

[0060] The inflammatory cell infiltration in the positive drug group was similar to that in the high-dose banana extract group.

[0061] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. Application of banana fruit extract in the preparation of drugs for treating acute gouty arthritis.

2. The application according to claim 1, characterized in that: The drug is used to treat acute gouty arthritis in mammals.

3. The application according to claim 1, characterized in that: The drug is administered orally via gavage, with an administration period of not less than 72 hours.

4. The application according to claim 1, characterized in that: In the drug, the volume ratio of banana fruit extract to physiological saline is 1:10 to 1:

100.

5. The application according to claim 4, characterized in that: The dosage of the drug is 2 mL per dose, twice daily.

6. The application according to claim 1, characterized in that: The drug is used to reduce inflammation of the synovial tissue.

7. The application according to claim 1, characterized in that: The drug is a drug that reduces the infiltration of inflammatory cells in synovial tissue.

8. The application according to any one of claims 1 to 7, characterized in that: The banana fruit extract is prepared by the following method: mature banana trees are harvested, and their stems, leaves and bark are taken, washed and broken into 2-3 cm fragments as the extract; the extract is soaked in a 20%-30% NaCl solution and heated with far-infrared light with a wavelength of 7.5-9.5 μm for 8-10 hours. The crude extract was extracted by cell wall disruption at -40℃ to 0℃ for 1 to 12 hours; the fiber and liquid were separated by centrifugation, and the liquid was filtered and allowed to stand; the supernatant was introduced into a fermentation tank lined with far-infrared stones with a spectral wavelength of 7.5 to 9.5 μm to obtain banana extract.

Images